Iterative Health Appoints New Chief Medical Officer for Hepatology and Obesity

Leadership Appointment Solidifies Company's Vested Interest in Advancing Research in Hepatology and Obesity

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Iterative Health, a healthcare technology and services company, has announced the appointment of Nadege Gunn, MD, as Chief Medical Officer, Hepatology and Obesity. Dr. Gunn is a globally recognized, board-certified gastroenterologist, hepatologist, obesity medicine specialist, and physician-scientist with over 15 years of experience as a principal investigator on clinical trials. In her new role, she will lead the advancement of hepatology and obesity research by overseeing medical affairs, development of specialized site operations, and strategic collaboration with biopharmaceutical sponsors and CRO partners.

Why it matters

This appointment underscores Iterative Health's commitment to building a leading, performance-driven research site network that expands access to innovative multispecialty therapies, while accelerating novel therapies to market faster. Dr. Gunn's expertise in metabolic and liver disease research, as well as her experience in translating complex protocols into high-performing, community-based research programs, will be valuable in advancing Iterative Health's hepatology and obesity portfolio.

The details

Dr. Gunn joins Iterative Health's senior leadership team and will provide strategic medical and scientific leadership across metabolic liver disease research and specialized site operations. She has a proven track record of translating complex protocols into high-performing, community-based research programs, and her research expertise spans the spectrum of liver disease, including MASH and MASLD.

  • Dr. Gunn's appointment was announced on February 12, 2026.

The players

Nadege Gunn, MD, CPI, DABOM, FAASLD

A globally recognized, board-certified gastroenterologist, hepatologist, obesity medicine specialist, and physician-scientist with more than 15 years of experience as a principal investigator on over 100 early- and late-phase clinical trials.

Iterative Health

A healthcare technology and services company powering the acceleration of clinical research to transform patient outcomes.

Dana Feuchtbaum

The Chief Operating Officer at Iterative Health, who was previously the Chief Product Officer.

Got photos? Submit your photos here. ›

What they’re saying

“Iterative Health has created an impressive foundation to advance hepatology and obesity research at scale. As a practicing physician and with experience as a principal investigator, I'm excited to join a team that is deeply focused on empowering providers and extending cutting-edge clinical research into the communities that care for these patients every day.”

— Nadege Gunn, MD, CPI, DABOM, FAASLD, Chief Medical Officer, Hepatology and Obesity, Iterative Health (Iterative Health)

“For providers and sponsors alike, Dr. Gunn strengthens the clinical leadership and operational confidence behind every hepatology and obesity study we support. Her appointment accelerates our ability to support increasingly complex hepatology and obesity trials at scale.”

— Dana Feuchtbaum, Chief Operating Officer, Iterative Health (Iterative Health)

What’s next

Iterative Health plans to continue expanding its therapeutic focus areas and global site network to support increasingly complex hepatology and obesity trials.

The takeaway

Iterative Health's appointment of Dr. Nadege Gunn as Chief Medical Officer for Hepatology and Obesity demonstrates the company's commitment to advancing research in these critical areas and building a leading, performance-driven research site network that can accelerate the development of innovative therapies.